MiNK Therapeutics, a clinical-stage biopharmaceutical company, reported strong financial results for Q3 2025.
The company showcased durable clinical responses in refractory solid tumors with their lead asset, agenT-797.
They launched collaborative studies focusing on GvHD and severe pulmonary diseases, backed by governmental and philanthropic funding.
The leadership team saw additions of renowned experts in pulmonary medicine and trauma, highlighting the company's advancement towards pivotal development.
Durable Clinical Responses with agenT-797
Clinical data showed sustained tumor regression and immune reprogramming, including >2-year complete remissions in refractory cancers.
Publication and Translational Momentum
Peer-reviewed publications validated agenT-797's ability to reinvigorate immune-exhausted T cells, supporting pivotal trials in oncology and inflammatory diseases.
Collaboration with UWCCC in GvHD
Initiation of a study with University of Wisconsin Carbone Cancer Center focused on preventing GvHD and reducing relapse in stem-cell transplant patients.
Strengthening of Leadership Team
Renowned experts in pulmonary and critical care medicine joined MiNK to lead late-stage ARDS and GvHD programs, enhancing the company's expertise.
- MiNK's strong financial position with $14.3 million in cash and additional equity sales provide runway through 2026, supporting multiple upcoming milestones.
- Clinical data showing durable responses with agenT-797 validate the potential of MiNK's iNKT cell therapies in treating cancer and immune disorders.
- Collaborative studies in GvHD and severe pulmonary diseases enhance MiNK's expansion into critical medical areas, with support from NIH and philanthropic partners.
- The addition of experts in pulmonary medicine and trauma to the leadership team signifies MiNK's strategic focus on advancing towards pivotal development in key therapeutic areas.
MiNK Therapeutics demonstrated significant progress in Q3 2025 with strong financial results, promising clinical data, and strategic collaborations in place. The company's focus on advancing the iNKT platform towards pivotal development across multiple medical fields highlights its commitment to innovative therapies and patient care.